Research Article: Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer
Introduction:
Triple negative breast cancer (TNBC), the most malignant subtype of breast cancer, , lacks expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER), rendering current endocrine and anti-HER therapies ineffective. , Chemotherapy remains the primary treatment method for TNBC. Lonidamine (LND), a small molecule chemotherapeutic drug, has shown promise in treating breast cancer by inducing apoptosis of tumor cells through depolarization of the mitochondrial…
Read more